

# Christopher E M Griffiths

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/177599/publications.pdf>

Version: 2024-02-01

728  
papers

53,819  
citations

1163

111  
h-index

2375

198  
g-index

756  
all docs

756  
docs citations

756  
times ranked

27745  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. <i>Journal of Investigative Dermatology</i> , 2013, 133, 377-385.	0.3	1,827
2	Secukinumab in Plaque Psoriasis – Results of Two Phase 3 Trials. <i>New England Journal of Medicine</i> , 2014, 371, 326-338.	13.9	1,675
3	Pathogenesis and clinical features of psoriasis. <i>Lancet, The</i> , 2007, 370, 263-271.	6.3	1,617
4	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. <i>Lancet, The</i> , 2005, 366, 1367-1374.	6.3	975
5	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010, 42, 985-990.	9.4	918
6	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2287-2303.	6.3	884
7	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012, 44, 1341-1348.	9.4	848
8	Psoriasis. <i>Lancet, The</i> , 2021, 397, 1301-1315.	6.3	792
9	Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. <i>New England Journal of Medicine</i> , 2010, 362, 118-128.	13.9	773
10	Keratinocytes as initiators of inflammation. <i>Lancet, The</i> , 1991, 337, 211-214.	6.3	724
11	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and Tj ETQq1 1 0.784314 rgBT / Overlock 10 Tf 5	6.3	719
12	Definition of treatment goals for moderate to severe psoriasis: a European consensus. <i>Archives of Dermatological Research</i> , 2011, 303, 1-10.	1.1	690
13	European S3 Guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1-70.	1.3	683
14	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 405-417.	0.6	673
15	A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. <i>British Journal of Dermatology</i> , 2005, 152, 1304-1312.	1.4	666
16	Psoriasis: epidemiology, clinical features, and quality of life. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, ii18-ii23.	0.5	605
17	Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. <i>Cut</i> , 2006, 55, 505-509.	6.1	524
18	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Tj ETQq0 0 0 rgBT / Overlock 10 Tf 5	0.6	498

#	ARTICLE	IF	CITATIONS
19	Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. <i>Journal of the American Academy of Dermatology</i> , 1989, 20, 617-629.	0.6	494
20	National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. <i>BMJ</i> , The, 2020, 369, m1590.	3.0	479
21	Restoration of Collagen Formation in Photodamaged Human Skin by Tretinoin (Retinoic Acid). <i>New England Journal of Medicine</i> , 1993, 329, 530-535.	13.9	464
22	British Association of Dermatologistsâ€™ guidelines for biologic interventions for psoriasis 2009. <i>British Journal of Dermatology</i> , 2009, 161, 987-1019.	1.4	412
23	Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. <i>British Journal of Dermatology</i> , 1989, 121, 421-431.	1.4	354
24	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5â€¦years of follow-up. <i>British Journal of Dermatology</i> , 2013, 168, 844-854.	1.4	350
25	Reduced Type I and Type III Procollagens in Photodamaged Adult Human Skin. <i>Journal of Investigative Dermatology</i> , 1995, 105, 285-290.	0.3	340
26	An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis. <i>Archives of Dermatology</i> , 2003, 139, 719-27.	1.7	338
27	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2015, 135, 2632-2640.	0.3	318
28	Application of Retinol to Human Skin In Vivo Induces Epidermal Hyperplasia and Cellular Retinoid Binding Proteins Characteristic of Retinoic Acid but Without Measurable Retinoic Acid Levels or Irritation. <i>Journal of Investigative Dermatology</i> , 1995, 105, 549-556.	0.3	277
29	Current and future management of psoriasis. <i>Lancet</i> , The, 2007, 370, 272-284.	6.3	268
30	Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: Further support that PTPN22 is an autoimmunity gene. <i>Arthritis and Rheumatism</i> , 2005, 52, 1694-1699.	6.7	266
31	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 83-98.e4.	0.6	264
32	A classification of psoriasis vulgaris according to phenotype. <i>British Journal of Dermatology</i> , 2007, 156, 258-262.	1.4	257
33	The contribution of perceptions of stigmatisation to disability in patients with psoriasis. <i>Journal of Psychosomatic Research</i> , 2001, 50, 11-15.	1.2	250
34	British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. <i>British Journal of Dermatology</i> , 2005, 153, 486-497.	1.4	245
35	Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. <i>British Journal of Dermatology</i> , 1999, 141, 185-191.	1.4	237
36	Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. <i>Archives of Dermatology</i> , 1994, 130, 727-733.	1.7	227

#	ARTICLE	IF	CITATIONS
37	Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. <i>British Journal of Dermatology</i> , 1993, 129, 415-421.	1.4	225
38	A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. <i>British Journal of Dermatology</i> , 2002, 146, 458-465.	1.4	218
39	Psychologic Factors in Psoriasis: Consequences, Mechanisms, and Interventions. <i>Dermatologic Clinics</i> , 2005, 23, 681-694.	1.0	212
40	REVIEW Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. <i>British Journal of Dermatology</i> , 2000, 142, 401-412.	1.4	211
41	Lichen planopilaris is characterized by immune privilege collapse of the hair follicle's epithelial stem cell niche. <i>Journal of Pathology</i> , 2013, 231, 236-247.	2.1	201
42	The Role of Adhesion Molecules, Chemotactic Factors, and Cytokines in Inflammatory and Neoplastic Skin Disease—1990 Update. <i>Journal of Investigative Dermatology</i> , 1990, 94, s151-s157.	0.3	199
43	Psychological Distress Impairs Clearance of Psoriasis in Patients Treated With Photochemotherapy. <i>Archives of Dermatology</i> , 2003, 139, 752-6.	1.7	199
44	Effect of Topical Cyclosporine Rinse on Oral Lichen Planus. <i>New England Journal of Medicine</i> , 1990, 323, 290-294.	13.9	196
45	Topical Tretinoin (Retinoic Acid) Therapy for Hyperpigmented Lesions Caused by Inflammation of the Skin in Black Patients. <i>New England Journal of Medicine</i> , 1993, 328, 1438-1443.	13.9	192
46	Genetic Analysis of PSORS1 Distinguishes Guttate Psoriasis and Palmoplantar Pustulosis. <i>Journal of Investigative Dermatology</i> , 2003, 120, 627-632.	0.3	190
47	Oral cyclosporine for the treatment of alopecia areata. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 242-250.	0.6	186
48	A Photonumeric Scale for the Assessment of Cutaneous Photodamage. <i>Archives of Dermatology</i> , 1992, 128, 347.	1.7	185
49	Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2006, 154, 977-978.	1.4	185
50	Expression of Growth Hormone Receptor, Insulin-Like Growth Factor 1 (IGF-1) and IGF-1 Receptor mRNA and Proteins in Human Skin. <i>Journal of Investigative Dermatology</i> , 1992, 99, 343-349.	0.3	181
51	Psychological stress, distress and disability in patients with psoriasis: Consensus and variation in the contribution of illness perceptions, coping and alexithymia. <i>British Journal of Clinical Psychology</i> , 2002, 41, 157-174.	1.7	179
52	Why Some Women Look Young for Their Age. <i>PLoS ONE</i> , 2009, 4, e8021.	1.1	178
53	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. <i>Rheumatology</i> , 2014, 53, 213-222.	0.9	177
54	Identification of ZNF313 / RNF114 as a novel psoriasis susceptibility gene. <i>Human Molecular Genetics</i> , 2008, 17, 1938-1945.	1.4	176

#	ARTICLE	IF	CITATIONS
55	Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. <i>British Journal of Dermatology</i> , 1999, 141, 1054-1060.	1.4	170
56	Topical Tretinoin (Retinoic Acid) Treatment for Liver Spots Associated with Photodamage. <i>New England Journal of Medicine</i> , 1992, 326, 368-374.	13.9	168
57	The spectrum of skin disorders in abdominal stoma patients. <i>British Journal of Dermatology</i> , 2000, 143, 1248-1260.	1.4	168
58	Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. <i>British Journal of Dermatology</i> , 2005, 152, 597-615.	1.4	165
59	Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. <i>British Journal of Dermatology</i> , 2017, 176, 650-658.	1.4	165
60	Clinical and genetic differences between pustular psoriasis subtypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1021-1026.	1.5	165
61	Psoriasis Prevalence in Adults in the United States. <i>JAMA Dermatology</i> , 2021, 157, 940.	2.0	165
62	Comparison of teleconsultations and face-to-face consultations: preliminary results of a United Kingdom multicentre teledermatology study. <i>British Journal of Dermatology</i> , 1998, 139, 81-87.	1.4	163
63	Glucocorticoid Sensitivity Is Determined by a Specific Glucocorticoid Receptor Haplotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 892-897.	1.8	163
64	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 277-286.e10.	0.6	163
65	Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF- $\alpha$ ) in allergic contact dermatitis (rhus dermatitis). <i>British Journal of Dermatology</i> , 1991, 124, 519-526.	1.4	158
66	Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 224-231.	0.6	157
67	Fibrillin-Rich Microfibrils are Reduced in Photoaged Skin. Distribution at the Dermal-Epidermal Junction. <i>Journal of Investigative Dermatology</i> , 1999, 112, 782-787.	0.3	156
68	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 928-938.	1.4	155
69	Fibrillin microfibrils are reduced in skin exhibiting striae distensae. <i>British Journal of Dermatology</i> , 1998, 138, 931-937.	1.4	153
70	Physical and psychologic measures are necessary to assess overall psoriasis severity. <i>Journal of the American Academy of Dermatology</i> , 2001, 45, 72-76.	0.6	153
71	AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. <i>American Journal of Human Genetics</i> , 2014, 94, 790-797.	2.6	153
72	What patients with psoriasis believe about their condition. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 196-201.	0.6	152

#	ARTICLE	IF	CITATIONS
73	Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 672-676.	0.5	149
74	Age-Associated Skin Conditions and Diseases: Current Perspectives and Future Options. <i>Gerontologist</i> , The, 2016, 56, S230-S242.	2.3	146
75	Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. <i>Archives of Dermatology</i> , 1990, 126, 339-350.	1.7	146
76	The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. <i>British Journal of Dermatology</i> , 1987, 116, 503-510.	1.4	145
77	Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. <i>British Journal of Dermatology</i> , 1997, 137, 755-760.	1.4	145
78	The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. <i>Journal of Clinical Investigation</i> , 2008, 118, 3151-3159.	3.9	145
79	Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 643-651.	0.6	142
80	Differential Expression of Peroxisome Proliferator-Activated Receptor Subtypes During the Differentiation of Human Keratinocytes. <i>Journal of Investigative Dermatology</i> , 1998, 111, 1116-1121.	0.3	141
81	Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1366-1369.	0.3	140
82	Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. <i>Journal of Medical Genetics</i> , 2007, 45, 114-116.	1.5	139
83	Single-Nucleotide Polymorphisms of Vascular Endothelial Growth Factor in Psoriasis of Early Onset. <i>Journal of Investigative Dermatology</i> , 2004, 122, 209-215.	0.3	138
84	Challenges and approaches for the development of safer immunomodulatory biologics. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 306-324.	21.5	138
85	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry—based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	1.5	136
86	Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. <i>British Journal of Dermatology</i> , 2002, 146, 824-831.	1.4	135
87	The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 548-554.	1.3	135
88	Treatment of pyoderma gangrenosum with cyclosporine. <i>Archives of Dermatology</i> , 1992, 128, 1060-1064.	1.7	135
89	Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2001, 145, 438-445.	1.4	133
90	Review Article: A new wrinkle on old skin: the role of elastic fibres in skin ageing. <i>International Journal of Cosmetic Science</i> , 2010, 32, 330-339.	1.2	133

#	ARTICLE	IF	CITATIONS
91	Ciclosporin in psoriasis clinical practice: an international consensus statement. <i>British Journal of Dermatology</i> , 2004, 150, 11-23.	1.4	132
92	Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2189-2197.	0.3	132
93	A photonumeric scale for the assessment of cutaneous photodamage. <i>Archives of Dermatology</i> , 1992, 128, 347-351.	1.7	131
94	The Salford Psoriasis Index: an holistic measure of psoriasis severity. <i>British Journal of Dermatology</i> , 2000, 142, 728-732.	1.4	130
95	Langerhans cell migration. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 413-418.	0.6	130
96	Adherence to treatment in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 370-379.	1.3	128
97	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2120-2130.	1.5	128
98	Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. <i>British Journal of Dermatology</i> , 2003, 149, 323-331.	1.4	127
99	The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. <i>Journal of Psychosomatic Research</i> , 2004, 57, 195-200.	1.2	127
100	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2015, 172, 1395-1406.	1.4	127
101	Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. <i>British Journal of Dermatology</i> , 1997, 137, 755-760.	1.4	126
102	Parastomal pyoderma gangrenosum: Clinical features and management. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 992-1002.	0.6	126
103	Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. <i>British Journal of Dermatology</i> , 2005, 153, 1192-1199.	1.4	125
104	Guideline for anti-TNF- $\alpha$ therapy in psoriatic arthritis. <i>Rheumatology</i> , 2005, 44, 390-397.	0.9	125
105	Adherence to medication in patients with psoriasis: a systematic literature review. <i>British Journal of Dermatology</i> , 2013, 168, 20-31.	1.4	125
106	Intermittent short courses of cyclosporin (Neoral <sup>®</sup> ) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. <i>British Journal of Dermatology</i> , 1999, 141, 283-291.	1.4	124
107	Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 648-653.	0.6	122
108	The role of neuropeptides in psoriasis. <i>British Journal of Dermatology</i> , 2006, 155, 876-882.	1.4	122



#	ARTICLE	IF	CITATIONS
109	Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 3705-3709.	6.7	122
110	Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. <i>British Journal of Dermatology</i> , 2011, 164, 862-872.	1.4	121
111	A Genome-Wide Association Study Identifies the Skin Color Genes IRF4, MC1R, ASIP, and BNC2 Influencing Facial Pigmented Spots. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1735-1742.	0.3	117
112	Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. <i>British Journal of Dermatology</i> , 2004, 151, 1227-1233.	1.4	116
113	Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2006, 154, 1161-1168.	1.4	116
114	Striae gravidarum in primiparae. <i>British Journal of Dermatology</i> , 2006, 155, 965-969.	1.4	116
115	Damage to Skin Extracellular Matrix Induced by UV Exposure. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 1063-1077.	2.5	116
116	Tumour necrosis factor- $\alpha$ -induced migration of human Langerhans cells: the influence of ageing. <i>British Journal of Dermatology</i> , 2002, 146, 32-40.	1.4	114
117	Acute or Chronic Topical Retinoic Acid Treatment of Human Skin In Vivo Alters the Expression of Epidermal Transglutaminase, Loricrin, Involucrin, Filaggrin, and Keratins 6 and 13 but not Keratins 1, 10, and 14. <i>Journal of Investigative Dermatology</i> , 1992, 98, 343-350.	0.3	110
118	Impaired Langerhans cell migration in psoriasis. <i>Journal of Experimental Medicine</i> , 2006, 203, 953-960.	4.2	109
119	Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1925-1929.	0.3	109
120	The global state of psoriasis disease epidemiology: a workshop report. <i>British Journal of Dermatology</i> , 2017, 177, e4-e7.	1.4	109
121	Alcohol consumption and psychological distress in patients with psoriasis. <i>British Journal of Dermatology</i> , 2007, 158, 071115063928007-???	1.4	108
122	The British Association of Dermatologists'™ Biologic Interventions Register (BADBIR): design, methodology and objectives. <i>British Journal of Dermatology</i> , 2012, 166, 545-554.	1.4	108
123	Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. <i>British Journal of Dermatology</i> , 2001, 145, 546-553.	1.4	107
124	Natural killer and natural killer-T cells in psoriasis. <i>Archives of Dermatological Research</i> , 2002, 294, 363-369.	1.1	107
125	Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2017, 176, 890-901.	1.4	107
126	Psychological influences in psoriasis. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 338-342.	0.6	106



#	ARTICLE	IF	CITATIONS
127	Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. <i>Arthritis and Rheumatism</i> , 2009, 61, 1103-1111.	6.7	106
128	Differential Regulation of Retinoic Acid Receptors and Binding Proteins in Human Skin. <i>Journal of Investigative Dermatology</i> , 1992, 98, 673-679.	0.3	105
129	Patients with psoriasis and their compliance with medication. <i>Journal of the American Academy of Dermatology</i> , 1999, 41, 581-583.	0.6	105
130	Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: A randomized trial. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 83-90.	0.6	105
131	Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. <i>British Journal of Dermatology</i> , 2005, 153, 1114-1120.	1.4	105
132	Interaction between Genetic Control of Vascular Endothelial Growth Factor Production and Retinoid Responsiveness in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2006, 126, 453-459.	0.3	105
133	Cytokines and Langerhans cell mobilisation in mouse and man. <i>Cytokine</i> , 2005, 32, 67-70.	1.4	104
134	Management of primary cicatricial alopecias: options for treatment. <i>British Journal of Dermatology</i> , 2008, 159, 1-22.	1.4	104
135	Assessing illness-related stress in psoriasis: The psychometric properties of the Psoriasis Life Stress Inventory. <i>Journal of Psychosomatic Research</i> , 1997, 42, 467-475.	1.2	103
136	Gamma interferon induces different keratinocyte cellular patterns of expression of HLA-DR and DQ and intercellular adhesion molecule-1 (ICAM-1) antigens. <i>British Journal of Dermatology</i> , 1989, 120, 1-7.	1.4	102
137	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 731-741.	0.6	101
138	Two Concentrations of Topical Tretinoin (Retinoic Acid) Cause Similar Improvement of Photoaging but Different Degrees of Irritation. <i>Archives of Dermatology</i> , 1995, 131, 1037.	1.7	100
139	Intralesional cyclosporine in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 94-100.	0.6	98
140	Topical tacrolimus in the management of peristomal pyoderma gangrenosum. <i>Journal of Dermatological Treatment</i> , 2001, 12, 13-17.	1.1	98
141	Tissue section AFM: In situ ultrastructural imaging of native biomolecules. <i>Matrix Biology</i> , 2010, 29, 254-260.	1.5	98
142	IL-1 $\beta$ -induced Langerhans cell migration and TNF- $\alpha$ production in human skin: regulation by lactoferrin. <i>Clinical and Experimental Immunology</i> , 2003, 132, 352-359.	1.1	97
143	Targeting cognitive-behaviour therapy to patients' implicit model of psoriasis: Results from a patient preference controlled trial. <i>British Journal of Clinical Psychology</i> , 2004, 43, 65-82.	1.7	97
144	The clinical identification and quantification of photodamage. <i>British Journal of Dermatology</i> , 1992, 127, 37-42.	1.4	96

#	ARTICLE	IF	CITATIONS
145	How not to get scar(r)ed: pointers to the correct diagnosis in patients with suspected primary cicatricial alopecia. <i>British Journal of Dermatology</i> , 2009, 160, 482-501.	1.4	96
146	Topical tretinoin (retinoic acid) treatment of hyperpigmented lesions associated with photoaging in Chinese and Japanese patients: A vehicle-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 76-84.	0.6	95
147	Patient satisfaction with teledermatology is related to perceived quality of life. <i>British Journal of Dermatology</i> , 2001, 145, 911-917.	1.4	95
148	Therapeutic strategies for psoriasis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 1-10.	0.7	94
149	Pathological worrying, illness perceptions and disease severity in patients with psoriasis. <i>British Journal of Health Psychology</i> , 2000, 5, 71-82.	1.9	94
150	Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 677-682.	0.5	92
151	Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-CABLE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 119-126.	1.3	92
152	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
153	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions. <i>JAMA Dermatology</i> , 2018, 154, 676.	2.0	90
154	Tumour necrosis factor- $\alpha$ induces Langerhans cell migration in humans. <i>British Journal of Dermatology</i> , 1999, 141, 192-200.	1.4	89
155	Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2964-2970.	0.3	89
156	Association of Psoriasis With the Risk of Developing or Dying of Cancer. <i>JAMA Dermatology</i> , 2019, 155, 1390.	2.0	89
157	Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1374-1382.	1.3	88
158	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Therapeutics Update). <i>Journal of the British Association of Dermatologists</i> , 2017, 177, 1017-1024.	1.0	88
159	Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologics and Therapeutics Update register. <i>British Journal of Dermatology</i> , 2015, 173, 510-518.	1.4	87
160	Inflammaging and the Skin. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1087-1095.	0.3	87
161	A pilot study examining mindfulness-based cognitive therapy in psoriasis. <i>Psychology, Health and Medicine</i> , 2015, 20, 121-127.	1.3	86
162	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86

#	ARTICLE	IF	CITATIONS
163	Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. <i>British Journal of Dermatology</i> , 1998, 138, 77-83.	1.4	85
164	Circulating natural killer cells in psoriasis. <i>British Journal of Dermatology</i> , 2003, 149, 160-164.	1.4	85
165	The Major Psoriasis Susceptibility Locus PSORS1 Is not a Risk Factor for Late-Onset Psoriasis. <i>Journal of Investigative Dermatology</i> , 2005, 124, 103-106.	0.3	85
166	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). <i>British Journal of Dermatology</i> , 2020, 183, 294-302.	1.4	85
167	Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. A double-blind, vehicle-controlled comparison of 0.1% and 0.025% tretinoin creams. <i>Archives of Dermatology</i> , 1995, 131, 1037-1044.	1.7	84
168	A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2001, 145, 886-890.	1.4	83
169	Differential modulation of keratinocyte intercellular adhesion molecule-1 expression by gamma interferon and phorbol ester: evidence for involvement of protein kinase C signal transduction. <i>British Journal of Dermatology</i> , 1990, 122, 333-342.	1.4	82
170	Exogenous topical lactoferrin inhibits allergen-induced Langerhans cell migration and cutaneous inflammation in humans. <i>British Journal of Dermatology</i> , 2001, 144, 715-725.	1.4	82
171	Does psychosocial stress play a role in the exacerbation of psoriasis?. <i>British Journal of Dermatology</i> , 2013, 169, 965-974.	1.4	82
172	Differential Expression of Protein Kinase C Isoenzymes in Normal and Psoriatic Adult Human Skin: Reduced Expression of Protein Kinase C- $\beta$ 2 in Psoriasis. <i>Journal of Investigative Dermatology</i> , 1993, 101, 553-559.	0.3	81
173	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>British Journal of Dermatology</i> , 2018, 178, 674-681.	1.4	80
174	Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. <i>British Journal of Dermatology</i> , 1999, 141, 279-282.	1.4	79
175	An in vivo experimental model for effects of topical retinoic acid in human skin. <i>British Journal of Dermatology</i> , 1993, 129, 389-394.	1.4	78
176	Update on the use of ciclosporin in immune-mediated dermatoses. <i>British Journal of Dermatology</i> , 2006, 155, 1-16.	1.4	78
177	Cytokine gene polymorphisms in psoriasis. <i>British Journal of Dermatology</i> , 2001, 144, 849-853.	1.4	77
178	Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 260-267.	4.0	77
179	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 70-79.e3.	0.6	77
180	Topical tretinoin (retinoic acid) improves early stretch marks. <i>Archives of Dermatology</i> , 1996, 132, 519-526.	1.7	77

#	ARTICLE	IF	CITATIONS
181	Paraneoplastic pemphigus presenting as a lichen planus pemphigoides-like eruption. Archives of Dermatology, 1993, 129, 866-869.	1.7	76
182	Long-term cyclosporin for psoriasis. British Journal of Dermatology, 1989, 120, 253-260.	1.4	75
183	Macrophage Migration Inhibitory Factor Gene Polymorphism is Associated with Psoriasis. Journal of Investigative Dermatology, 2004, 123, 484-487.	0.3	74
184	Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. British Journal of Dermatology, 2006, 154, 345-352.	1.4	74
185	Polymorphisms in the IL-12 $\beta$ 2 and IL-23R Genes Are Associated with Psoriasis of Early Onset in a UK Cohort. Journal of Investigative Dermatology, 2008, 128, 1325-1327.	0.3	74
186	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 2018, 154, 581.	2.0	74
187	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 2019, 180, 1069-1076.	1.4	74
188	Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. Journal of the American Academy of Dermatology, 2005, 52, 468-473.	0.6	73
189	Alexithymia in patients with psoriasis. Journal of Psychosomatic Research, 2005, 58, 89-96.	1.2	73
190	Nailfold video capillaroscopy in psoriasis. British Journal of Dermatology, 2000, 142, 1171-1176.	1.4	72
191	Systemic ciclosporin and tacrolimus in dermatology. Dermatologic Therapy, 2007, 20, 239-250.	0.8	72
192	A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. British Journal of Dermatology, 2008, 159, 942-951.	1.4	71
193	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2018, 138, 775-784.	0.3	71
194	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology, 2020, 82, 936-945.	0.6	71
195	Stimulus-Selective Induction of CRABP-II mRNA: A Marker for Retinoic Acid Action in Human Skin. Journal of Investigative Dermatology, 1993, 100, 356-359.	0.3	70
196	A Short-Term Screening Protocol, Using Fibrillin-1 as a Reporter Molecule, for Photoaging Repair Agents. Journal of Investigative Dermatology, 2001, 116, 672-678.	0.3	70
197	Epidermal Langerhans cell migration and sensitisation to chemical allergens. Apms, 2003, 111, 797-804.	0.9	70
198	Altered claudin expression is a feature of chronic plaque psoriasis. Journal of Pathology, 2007, 212, 450-458.	2.1	70

#	ARTICLE	IF	CITATIONS
199	Multiple switches between <sc>GP</sc>2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory <sc>EGALITY</sc> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 420-427.	1.3	70
200	A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. <i>Pharmacogenomics</i> , 2011, 12, 815-826.	0.6	69
201	Recognition of need in health care consultations: a qualitative study of people with psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 354-361.	1.4	69
202	The role of beliefs: lessons from a pilot study on illness perception, psychological distress and quality of life in patients with primary cicatricial alopecia. <i>British Journal of Dermatology</i> , 2015, 172, 130-137.	1.4	69
203	The impact of intrinsic ageing on the protein composition of the dermal-epidermal junction. <i>Mechanisms of Ageing and Development</i> , 2016, 156, 14-16.	2.2	69
204	Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. <i>British Journal of Dermatology</i> , 2004, 151, 1219-1226.	1.4	68
205	Evidence to support <i>IL-13</i> as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1016-1019.	0.5	68
206	The macrolide immunosuppressants in dermatology: mechanisms of action. <i>European Journal of Dermatology</i> , 2002, 12, 618-22.	0.3	68
207	Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 27-29.	0.6	67
208	Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. <i>Clinics in Dermatology</i> , 2008, 26, 438-447.	0.8	67
209	Inhibition of IL-17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections. <i>Clinical and Translational Immunology</i> , 2017, 6, e152.	1.7	67
210	Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2002, 146, 414-422.	1.4	66
211	Repair of photoaged dermal matrix by topical application of a cosmetic "anti-ageing" product. <i>British Journal of Dermatology</i> , 2008, 158, 472-477.	1.4	66
212	A cosmetic "anti-ageing" product improves photoaged skin: a double-blind, randomized controlled trial. <i>British Journal of Dermatology</i> , 2009, 161, 419-426.	1.4	66
213	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3596-3602.	6.7	65
214	Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. <i>British Journal of Dermatology</i> , 2016, 174, 985-995.	1.4	65
215	Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*. <i>British Journal of Dermatology</i> , 2021, 184, 243-258.	1.4	65
216	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. <i>British Journal of Dermatology</i> , 2009, 160, 438-441.	1.4	64

#	ARTICLE	IF	CITATIONS
217	Lichen planopilaris following hair transplantation and face-lift surgery. <i>British Journal of Dermatology</i> , 2012, 166, 666-370.	1.4	64
218	A novel, web-based, psychological intervention for people with psoriasis: the electronic Targeted Intervention for Psoriasis (eTIPs) study. <i>British Journal of Dermatology</i> , 2013, 169, 329-336.	1.4	64
219	A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. <i>British Journal of Dermatology</i> , 2018, 179, 173-181.	1.4	64
220	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1584-1591.	0.3	63
221	P16INK4a Positive Cells in Human Skin Are Indicative of Local Elastic Fiber Morphology, Facial Wrinkling, and Perceived Age. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 1022-1028.	1.7	62
222	Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018, 138, 534-541.	0.3	62
223	Sulfasalazine improves psoriasis. A double-blind analysis. <i>Archives of Dermatology</i> , 1990, 126, 487-493.	1.7	62
224	Methotrexate for psoriasis in the era of biological therapy. <i>Clinical and Experimental Dermatology</i> , 2008, 33, 551-554.	0.6	61
225	Psoriasis and Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2017, 7, 31-41.	1.4	60
226	Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 115-123.	0.3	60
227	Patients' strategies for coping with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2002, 27, 177-184.	0.6	59
228	Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. <i>British Journal of Dermatology</i> , 2012, 166, 474-482.	1.4	59
229	Psoriasis, T Cells and Autoimmunity. <i>Journal of the Royal Society of Medicine</i> , 1996, 89, 315-319.	1.1	58
230	Folliculitis decalvans. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 120-122.	0.6	58
231	Balancing the Benefits and Risks of Drug Treatment. <i>Archives of Dermatology</i> , 2007, 143, 1175-9.	1.7	58
232	Low-dose ultraviolet radiation selectively degrades chromophore-rich extracellular matrix components. <i>Journal of Pathology</i> , 2010, 222, 32-40.	2.1	58
233	Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic. <i>British Journal of Dermatology</i> , 2020, 183, 792-794.	1.4	58
234	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blind trial*. <i>British Journal of Dermatology</i> , 2021, 184, 1047-1058.	1.4	58



#	ARTICLE	IF	CITATIONS
235	Quality of life measures in psoriasis: a critical appraisal of their quality. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1998, 23, 391-398.	0.7	57
236	Peristomal dermatoses: A novel indication for topical steroid lotions. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 679-682.	0.6	57
237	Nuclear Hormone Receptors in Human Skin. <i>Hormone and Metabolic Research</i> , 2007, 39, 96-105.	0.7	57
238	Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. <i>British Journal of Dermatology</i> , 2018, 178, 132-139.	1.4	57
239	Illness perception in individuals with atopic dermatitis. <i>Psychology, Health and Medicine</i> , 2007, 12, 433-444.	1.3	56
240	Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial. <i>Dermatology</i> , 2010, 221, 172-178.	0.9	55
241	“On the surface”: a qualitative study of GPs’ and patients’ perspectives on psoriasis. <i>BMC Family Practice</i> , 2013, 14, 158.	2.9	55
242	TOPICAL CYCLOSPORIN AND PSORIASIS. <i>Lancet</i> , The, 1987, 329, 806.	6.3	54
243	Antistreptococcal interventions for guttate and chronic plaque psoriasis. <i>The Cochrane Library</i> , 2000, , CD001976.	1.5	54
244	Lactoferrin: influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation. <i>Biochemistry and Cell Biology</i> , 2002, 80, 103-107.	0.9	54
245	Defining cancer risk in dermatomyositis. Part I. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 451-455.	0.6	54
246	The Simplified Psoriasis Index (SPI): A Practical Tool for Assessing Psoriasis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1956-1962.	0.3	54
247	Structural and compositional diversity of fibrillin microfibrils in human tissues. <i>Journal of Biological Chemistry</i> , 2018, 293, 5117-5133.	1.6	54
248	The role of the microbiome in psoriasis: moving from disease description to treatment selection?. <i>British Journal of Dermatology</i> , 2018, 178, 1020-1027.	1.4	54
249	Clinical improvement following dermabrasion of photoaged skin correlates with synthesis of collagen I. <i>Archives of Dermatology</i> , 1994, 130, 1136-1142.	1.7	54
250	An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 300-12.	0.4	54
251	Recent advances in cutaneous angiogenesis. <i>British Journal of Dermatology</i> , 2002, 147, 418-425.	1.4	53
252	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. <i>British Journal of Dermatology</i> , 2005, 152, 1219-1227.	1.4	53



#	ARTICLE	IF	CITATIONS
253	Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. <i>Genes and Immunity</i> , 2009, 10, 654-658.	2.2	53
254	Differential Modulation of Transforming Growth Factor- $\beta$ 1 Expression and Mucin Deposition by Retinoic Acid and Sodium Lauryl Sulfate in Human Skin. <i>Journal of Investigative Dermatology</i> , 1992, 98, 102-108.	0.3	52
255	The immunological basis of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 1-5.	1.3	52
256	Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. <i>British Journal of Dermatology</i> , 2005, 153, 549-551.	1.4	52
257	The role of retinoids in the prevention and repair of aged and photoaged skin. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 613-618.	0.6	51
258	Naevus sebaceus: a mosaic RASopathy. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 1-6.	0.6	51
259	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	1.4	51
260	Clinical features of photodamaged human skin are associated with a reduction in collagen VII. <i>British Journal of Dermatology</i> , 1997, 137, 344-350.	1.4	51
261	Lymphocyte Trafficking in Psoriasis: A New Perspective Emphasizing the Dermal Dendrocyte with Active Dermal Recruitment Mediated Via Endothelial Cells Followed by Intra-Epidermal T-Cell Activation. <i>Journal of Investigative Dermatology</i> , 1990, 95, S35-S37.	0.3	50
262	Divergent Beliefs About Psoriasis Are Associated with Increased Psychological Distress. <i>Journal of Investigative Dermatology</i> , 2004, 123, 49-56.	0.3	50
263	The use of retinoids in the treatment of photoaging. <i>Dermatologic Therapy</i> , 2006, 19, 297-305.	0.8	50
264	A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2006, 17, 90-95.	1.1	50
265	Evidence for the presence of bacteria in the blood of psoriasis patients. <i>Archives of Dermatological Research</i> , 2010, 302, 495-498.	1.1	50
266	The global challenge for skin health. <i>British Journal of Dermatology</i> , 2015, 172, 1469-1472.	1.4	50
267	Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. <i>Journal of Dermatological Treatment</i> , 2015, 26, 103-112.	1.1	50
268	Organization of the dermal matrix impacts the biomechanical properties of skin. <i>British Journal of Dermatology</i> , 2017, 177, 818-827.	1.4	50
269	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2017, 176, 1297-1307.	1.4	50
270	Novel immune-based therapies for psoriasis. <i>British Journal of Dermatology</i> , 2002, 146, 546-551.	1.4	49

#	ARTICLE	IF	CITATIONS
271	Diminished Neural and Cognitive Responses to Facial Expressions of Disgust in Patients with Psoriasis: A Functional Magnetic Resonance Imaging Study. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2613-2619.	0.3	49
272	The Effects of Acute Social Stress on Epidermal Langerhans' Cell Frequency and Expression of Cutaneous Neuropeptides. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1273-1279.	0.3	48
273	Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. <i>British Journal of Dermatology</i> , 2009, 160, 162-169.	1.4	48
274	Patient-reported outcome measures in psoriasis: the good, the bad and the missing!. <i>British Journal of Dermatology</i> , 2015, 172, 1210-1221.	1.4	48
275	Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength. <i>Journal of Investigative Dermatology</i> , 2018, 138, 785-794.	0.3	48
276	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1367-1374.	0.6	48
277	Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. <i>British Journal of Dermatology</i> , 2002, 147, 299-307.	1.4	47
278	A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 483-486.	0.6	47
279	Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1440-1448.	1.3	47
280	Cytokine blocking agents in dermatology. <i>Clinical and Experimental Dermatology</i> , 2002, 27, 585-590.	0.6	46
281	Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis. <i>Journal of Behavioral Medicine</i> , 2003, 26, 211-224.	1.1	46
282	Interventions for chronic palmoplantar pustulosis. <i>The Cochrane Library</i> , 2006, , CD001433.	1.5	46
283	Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. <i>Current Medical Research and Opinion</i> , 2008, 24, 1237-1254.	0.9	46
284	The 2016 International League of Dermatological Societies' revised glossary for the description of cutaneous lesions. <i>British Journal of Dermatology</i> , 2016, 174, 1351-1358.	1.4	46
285	Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. <i>British Journal of Dermatology</i> , 2020, 183, 128-138.	1.4	46
286	The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. <i>Archives of Dermatological Research</i> , 2008, 300, 537-544.	1.1	45
287	Facial Appearance Reflects Human Familial Longevity and Cardiovascular Disease Risk in Healthy Individuals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013, 68, 145-152.	1.7	45
288	Skin health in older age. <i>Maturitas</i> , 2014, 79, 256-264.	1.0	45

#	ARTICLE	IF	CITATIONS
289	A potential role for endogenous proteins as sacrificial sunscreens and antioxidants in human tissues. <i>Redox Biology</i> , 2015, 5, 101-113.	3.9	45
290	Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. <i>Expert Review of Dermatology</i> , 2008, 3, 657-665.	0.3	44
291	A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1052-1059.	1.4	44
292	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. <i>American Journal of Human Genetics</i> , 2020, 107, 539-543.	2.6	44
293	Measurement, Classification and Evaluation of Sleep Disturbance in Psoriasis: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0157843.	1.1	44
294	Comparison of CD271 (Adapalene) and All-Trans Retinoic Acid in Human Skin: Dissociation of Epidermal Effects and CRABP-II mRNA Expression. <i>Journal of Investigative Dermatology</i> , 1993, 101, 325-328.	0.3	43
295	Aging in Skin of Color: Disruption to Elastic Fiber Organization Is Detrimental to Skin's Biomechanical Function. <i>Journal of Investigative Dermatology</i> , 2019, 139, 779-788.	0.3	42
296	Psoriasis: the future. <i>British Journal of Dermatology</i> , 2001, 144, 37-43.	1.4	41
297	Stigmatization and psoriasis. <i>British Journal of Dermatology</i> , 2003, 149, 209-211.	1.4	41
298	Filaggrin Null Alleles Are Not Associated with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1878-1882.	0.3	41
299	Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. <i>British Journal of Dermatology</i> , 2008, 158, 962-968.	1.4	41
300	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. <i>Human Molecular Genetics</i> , 2017, 26, 4301-4313.	1.4	41
301	Failure of reticular erythematous mucinosis to respond to cyclosporine. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 825-828.	0.6	40
302	Prolonged occlusion in the treatment of psoriasis: A clinical and immunohistologic study. <i>Journal of the American Academy of Dermatology</i> , 1995, 32, 618-622.	0.6	40
303	A comparison of wire brush and diamond fraisesuperficial dermabrasion for photoaged skin. <i>Journal of the American Academy of Dermatology</i> , 1996, 34, 235-243.	0.6	40
304	Basal cell carcinoma. <i>Cancer</i> , 2000, 89, 1012-1018.	2.0	40
305	Interventions for photodamaged skin. , 2005, , CD001782.		40
306	Mind the (Gender) Gap: Does Prolactin Exert Gender and/or Site-Specific Effects on the Human Hair Follicle?. <i>Journal of Investigative Dermatology</i> , 2010, 130, 886-891.	0.3	40

#	ARTICLE	IF	CITATIONS
307	Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 667-676.	1.4	40
308	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	1.4	40
309	Exacerbation of psoriasis by indomethacin. <i>British Journal of Dermatology</i> , 1987, 117, 799-800.	1.4	39
310	Distribution and expression of type VI collagen in photoaged skin. <i>British Journal of Dermatology</i> , 2001, 144, 751-759.	1.4	39
311	Photoageing: the darker side of the sun. <i>Photochemical and Photobiological Sciences</i> , 2006, 5, 160-164.	1.6	39
312	Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1371-1377.	1.3	39
313	In search of oral psoriasis. <i>Archives of Dermatological Research</i> , 2012, 304, 1-5.	1.1	39
314	Expression of microRNA-184 in keratinocytes represses argonaute 2. <i>Journal of Cellular Physiology</i> , 2013, 228, 2314-2323.	2.0	39
315	Motivational interviewing-based training enhances clinicians' skills and knowledge in psoriasis: findings from the Pso Well study. <i>British Journal of Dermatology</i> , 2017, 176, 677-686.	1.4	39
316	Ageing significantly impacts the biomechanical function and structural composition of skin. <i>Experimental Dermatology</i> , 2019, 28, 981-984.	1.4	39
317	Clinical features of photodamaged human skin are associated with a reduction in collagen VII. <i>British Journal of Dermatology</i> , 1997, 137, 344-350.	1.4	38
318	Oral mucosal keratinocytes express RANTES and ICAM-1, but not interleukin-8, in oral lichen planus and oral lichenoid reactions induced by amalgam fillings. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 64-69.	0.6	38
319	Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 561-565.	0.6	38
320	Acne conglobata and adalimumab: use of tumour necrosis factor- $\alpha$ antagonists in treatment-resistant acne conglobata, and review of the literature. <i>Clinical and Experimental Dermatology</i> , 2015, 40, 383-386.	0.6	38
321	Aberrant Intercellular Adhesion Molecule-1 (ICAM-1) Expression by Hair-Follicle Epithelial Cells and Endothelial Leukocyte Adhesion Molecule-1 (ELAM-1) by Vascular Cells Are Important Adhesion-Molecule Alterations in Alopecia Areata. <i>Journal of Investigative Dermatology</i> , 1991, 96, S91-S92.	0.3	37
322	Cellular Localization of mRNA for Cellular Retinoic Acid-Binding Protein II and Nuclear Retinoic Acid Receptor- $\beta$ 1 in Retinoic Acid-Treated Human Skin. <i>Journal of Investigative Dermatology</i> , 1992, 99, 146-150.	0.3	37
323	Differential Regulation of Tyrosinase Activity in Skin of White and Black Individuals In Vivo by Topical Retinoic Acid. <i>Journal of Investigative Dermatology</i> , 1993, 100, 800-805.	0.3	37
324	Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. <i>British Journal of Dermatology</i> , 1999, 140, 562-564.	1.4	37

#	ARTICLE	IF	CITATIONS
325	Pathogenic aspects of cutaneous photoaging. <i>Journal of Cosmetic Dermatology</i> , 2005, 4, 230-236.	0.8	37
326	Infliximab for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 797-805.	1.4	37
327	Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles <i>in vitro</i> . <i>British Journal of Dermatology</i> , 2010, 162, 1127-1131.	1.4	37
328	Topical sucralfate in the management of peristomal skin disease: an open study. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 584-588.	0.6	36
329	Alcohol-Related Mortality in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2017, 153, 1256.	2.0	36
330	Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register ( <i>scp</i> >BADBIR</i>scp> ). <i>British Journal of Dermatology</i> , 2019, 180, 329-337.	1.4	36
331	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. <i>British Journal of Dermatology</i> , 2021, 185, 1146-1159.	1.4	36
332	The Effects of Topical Treatment with Steroids or Dithranol on Epidermal T Lymphocytes and Dendritic Cells in Psoriasis. <i>Scandinavian Journal of Immunology</i> , 1985, 22, 471-477.	1.3	35
333	Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severity. <i>British Journal of Dermatology</i> , 2005, 152, 489-504.	1.4	35
334	Humoral Autoimmune Responses to the Squamous Cell Carcinoma Antigen Protein Family in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2219-2224.	0.3	35
335	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. <i>Archives of Dermatological Research</i> , 2016, 308, 201-205.	1.1	35
336	Digital teledermatology for skin tumours: A preliminary assessment using a receiver operating characteristics (ROC) analysis. <i>Journal of Telemedicine and Telecare</i> , 1999, 5, 57-58.	1.4	34
337	Increased Blood Levels of IgG Reactive with Secreted <i>Streptococcus pyogenes</i> Proteins in Chronic Plaque Psoriasis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1337-1342.	0.3	34
338	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. <i>British Journal of Dermatology</i> , 2012, 166, 189-195.	1.4	34
339	Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study. <i>British Journal of Dermatology</i> , 2019, 180, 108-115.	1.4	34
340	Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. <i>British Journal of Dermatology</i> , 2006, 155, 1236-1241.	1.4	33
341	Recommendations for the Long-Term Treatment of Psoriasis with Infliximab: A Dermatology Expert Group Consensus. <i>Dermatology</i> , 2008, 217, 268-275.	0.9	33
342	Topical photodynamic therapy following excisional wounding of human skin increases production of transforming growth factor- $\beta$ 3 and matrix metalloproteinases 1 and 9, with associated improvement in dermal matrix organization. <i>British Journal of Dermatology</i> , 2014, 171, 55-62.	1.4	33

#	ARTICLE	IF	CITATIONS
343	Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. <i>British Journal of Dermatology</i> , 2016, 175, 1038-1044.	1.4	33
344	Aged human skin accumulates mast cells with altered functionality that localize to macrophages and vasoactive intestinal peptide-positive nerve fibres. <i>British Journal of Dermatology</i> , 2019, 180, 849-858.	1.4	33
345	Topical Retinoic Acid for Photoaging: Clinical Response and Underlying Mechanisms. <i>Skin Pharmacology and Physiology</i> , 1993, 6, 70-77.	1.1	32
346	A systematic review of treatments for guttate psoriasis. <i>British Journal of Dermatology</i> , 2001, 145, 891-894.	1.4	32
347	Psoriasis: the future. <i>British Journal of Dermatology</i> , 2001, 144, 37-43.	1.4	32
348	Does collapse of immune privilege in the hair-follicle bulge play a role in the pathogenesis of primary cicatricial alopecia?. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 637-644.	0.6	32
349	Investigational VEGF antagonists for psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 33-43.	1.9	32
350	Responsiveness to Change and Interpretability of the Simplified Psoriasis Index. <i>Journal of Investigative Dermatology</i> , 2014, 134, 351-358.	0.3	32
351	Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. <i>British Journal of Dermatology</i> , 2014, 171, 485-491.	1.4	32
352	A Review and Update of the Clinical Uses of Cyclosporine in Dermatology. <i>Dermatologic Clinics</i> , 1991, 9, 805-817.	1.0	31
353	The ICAM-3/LFA-1 interaction is critical for epidermal Langerhans cell alloantigen presentation to CD4+ T cells. <i>British Journal of Dermatology</i> , 1995, 133, 823-829.	1.4	31
354	Immunopathogenesis and Immunotherapy of Psoriasis. <i>Dermatologic Clinics</i> , 1995, 13, 739-749.	1.0	31
355	Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 224-231.	1.3	31
356	Does message framing affect changes in behavioural intentions in people with psoriasis? A randomized exploratory study examining health risk communication. <i>Psychology, Health and Medicine</i> , 2018, 23, 763-778.	1.3	31
357	Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 826-832.	0.4	31
358	Induction of Proliferation of Growth-Inhibited Keratinocytes and Fibroblasts in Monolayer Culture by Sodium Lauryl Sulfate: Comparison with All-Trans Retinoic Acid. <i>Journal of Investigative Dermatology</i> , 1991, 97, 917-921.	0.3	30
359	Efficacy of anti-aging products for periorbital wrinkles as measured by 3D imaging. <i>Journal of Cosmetic Dermatology</i> , 2009, 8, 228-233.	0.8	30
360	"In someone's clinic but not in mine" - clinicians' views of supporting lifestyle behaviour change in patients with psoriasis: a qualitative interview study. <i>British Journal of Dermatology</i> , 2014, 171, 1116-1122.	1.4	30



#	ARTICLE	IF	CITATIONS
361	Establishing an Academicâ€“Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2903-2907.	0.3	30
362	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1235.	2.0	30
363	A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 100-107.	0.3	30
364	The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. <i>British Journal of Dermatology</i> , 2021, 185, 935-944.	1.4	30
365	Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. <i>British Journal of Dermatology</i> , 2021, 185, 646-648.	1.4	30
366	Short-Term Retinoic Acid Treatment Increases In Vivo, but Decreases In Vitro, Epidermal Transglutaminase-K Enzyme Activity and Immunoreactivity. <i>Journal of Investigative Dermatology</i> , 1992, 99, 283-288.	0.3	29
367	Inflammatory breast carcinoma (carcinoma erysipeloides): an easily overlooked diagnosis. <i>British Journal of Dermatology</i> , 1993, 129, 324-326.	1.4	29
368	Down-regulation of Langerhans cell protein kinase C- $\beta$ isoenzyme expression in inflammatory and hyperplastic dermatoses. <i>British Journal of Dermatology</i> , 1995, 133, 157-167.	1.4	29
369	The British Association of Dermatologists guidelines for the management of skin disease. <i>British Journal of Dermatology</i> , 1999, 141, 396-397.	1.4	29
370	The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 060628090810004-???	1.3	29
371	How best to halt and/or revert UV-induced skin ageing: strategies, facts and fiction. <i>Experimental Dermatology</i> , 2008, 17, 228-229.	1.4	29
372	Psoriasis: consensus on topical therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 859-870.	1.3	29
373	Can stress reduction interventions improve psoriasis? A review. <i>Psychology, Health and Medicine</i> , 2013, 18, 501-514.	1.3	29
374	Geographical ancestry is a key determinant of epidermal morphology and dermal composition. <i>British Journal of Dermatology</i> , 2014, 171, 274-282.	1.4	29
375	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). <i>American Journal of Clinical Dermatology</i> , 2017, 18, 273-280.	3.3	29
376	Novel approaches to characterize age-related remodelling of the dermal-epidermal junction in 2D, 3D and <i>in vivo</i> . <i>Skin Research and Technology</i> , 2017, 23, 131-148.	0.8	29
377	Lower levels of interleukin-1 $\beta$ gene expression are associated with impaired Langerhans cell migration in aged human skin. <i>Immunology</i> , 2018, 153, 60-70.	2.0	29
378	Incidence and prevalence of psoriasis in Israel between 2011 and 2017. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2075-2081.	1.3	29



#	ARTICLE	IF	CITATIONS
379	Selective proteolysis by matrix metalloproteinases of photo-oxidised dermal extracellular matrix proteins. <i>Cellular Signalling</i> , 2019, 54, 191-199.	1.7	29
380	Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy. <i>Archives of Dermatology</i> , 1992, 128, 786-790.	1.7	29
381	The impact of psoriasis guidelines on appropriateness of referral from primary to secondary care: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2006, 155, 393-400.	1.4	28
382	Proteomic analysis of suction blister fluid isolated from human skin. <i>Clinical and Experimental Dermatology</i> , 2006, 31, 445-448.	0.6	28
383	Evaluation of educational methods in dermatology and confidence levels: a national survey of UK medical students. <i>International Journal of Dermatology</i> , 2011, 50, 198-202.	0.5	28
384	A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.4	28
385	Differential expression of elastic fibre components in intrinsically aged skin. <i>Biogerontology</i> , 2012, 13, 37-48.	2.0	28
386	Interleukin 17-A inhibition in the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1-4.	1.3	28
387	“I should have taken that further” missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed-methods study. <i>Health Expectations</i> , 2016, 19, 1121-1137.	1.1	28
388	Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, S72-8.	0.4	28
389	Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. <i>European Journal of Dermatology</i> , 2007, 17, 381-6.	0.3	28
390	Immunological mechanisms involved in psoriasis. <i>Seminars in Immunopathology</i> , 1992, 13, 441-54.	4.0	27
391	Combination Regimens of Topical Calcipotriene in Chronic Plaque Psoriasis. <i>Archives of Dermatology</i> , 2000, 136, 1536-43.	1.7	27
392	The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. <i>British Journal of Dermatology</i> , 2005, 153, 869-873.	1.4	27
393	Salicyloyl-phytosphingosine: a novel agent for the repair of photoaged skin. <i>International Journal of Cosmetic Science</i> , 2007, 29, 319-329.	1.2	27
394	Care of patients with psoriasis: an audit of U.K. services in secondary care. <i>British Journal of Dermatology</i> , 2009, 160, 557-564.	1.4	27
395	A temporal analysis of the central neural processing of itch. <i>British Journal of Dermatology</i> , 2012, 166, 994-1001.	1.4	27
396	Functional magnetic resonance imaging in dermatology: The skin, the brain and the invisible. <i>Experimental Dermatology</i> , 2017, 26, 845-853.	1.4	27

#	ARTICLE	IF	CITATIONS
397	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 769-778.	1.3	27
398	Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. <i>British Journal of Dermatology</i> , 1996, 135, 60-64.	1.4	27
399	Systemic and local administration of cyclosporine in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 1242-1247.	0.6	26
400	Constitutive absence and interferon- $\beta$ -induced expression of adhesion molecules in basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 721-726.	0.6	26
401	All-trans retinoic acid compromises desmosome expression in human epidermis. <i>British Journal of Dermatology</i> , 1998, 139, 577-584.	1.4	26
402	Drug Treatment of Photoaged Skin. <i>Drugs and Aging</i> , 1999, 14, 289-301.	1.3	26
403	A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasis. <i>Experimental Dermatology</i> , 2003, 12, 506-509.	1.4	26
404	Exogenous interleukin-1beta restores impaired Langerhans cell migration in aged skin. <i>British Journal of Dermatology</i> , 2004, 150, 1217-1218.	1.4	26
405	Adversarial growth in patients undergoing treatment for psoriasis: A prospective study of the ability of patients to construe benefits from negative events. <i>Psychology, Health and Medicine</i> , 2005, 10, 44-56.	1.3	26
406	Pilot study of dual-wavelength (532 and 633nm) laser Doppler imaging and infrared thermography of morphea. <i>British Journal of Dermatology</i> , 2009, 160, 864-867.	1.4	26
407	Comparing biological therapies in psoriasis: implications for clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 10-14.	1.3	26
408	Polymorphisms in IL-1B Distinguish between Psoriasis of Early and Late Onset. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1459-1462.	0.3	26
409	Primary care-based screening for cardiovascular risk factors in patients with psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 348-356.	1.4	26
410	Risk of hospitalization and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink*. <i>British Journal of Dermatology</i> , 2021, 184, 78-86.	1.4	26
411	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.4	26
412	IgA anti-endomysial antibody detection in the serum of patients with dermatitis herpetiformis following gluten challenge. <i>Archives of Dermatological Research</i> , 1985, 277, 349-351.	1.1	25
413	Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. <i>British Journal of Dermatology</i> , 1996, 135, 60-64.	1.4	25
414	Danger signals and skin sensitization. <i>British Journal of Dermatology</i> , 2002, 147, 613-613.	1.4	25

#	ARTICLE	IF	CITATIONS
415	Measurement of cytokine expression and Langerhans cell migration in human skin following suction blister formation. <i>Experimental Dermatology</i> , 2004, 13, 452-460.	1.4	25
416	Severely Photosensitive Psoriasis: A Phenotypically Defined Patient Subset. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2861-2867.	0.3	25
417	Genotyping of immune-related genetic variants identifies <i>TYK2</i> as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1750-1752.	0.5	25
418	A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. <i>Rheumatology</i> , 2014, 53, 1422-1430.	0.9	25
419	â€New to meâ€™™: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well <sup>®</sup> patient materials mixedâ€methods feasibility study. <i>British Journal of Dermatology</i> , 2017, 177, 758-770.	1.4	25
420	Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. <i>Journal of Dermatological Treatment</i> , 2022, 33, 848-856.	1.1	25
421	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 123-134.	1.3	25
422	Tumour Necrosis Factor Alpha, Interferon Gamma and Substance P Are Novel Modulators of Extrapituitary Prolactin Expression in Human Skin. <i>PLoS ONE</i> , 2013, 8, e60819.	1.1	25
423	Human in vivo pharmacology of topical retinoids. <i>Archives of Dermatological Research</i> , 1994, 287, 53-60.	1.1	24
424	Topical retinoids and cutaneous biology. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 1-10.	0.6	24
425	Primary cicatricial alopecias: a U.K. survey. <i>British Journal of Dermatology</i> , 2012, 167, 694-697.	1.4	24
426	The risk of postâ€operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 86-91.	1.3	24
427	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1410-1421.	1.4	24
428	Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1523-1529.	1.3	24
429	Impaired Langerhans cell migration in psoriasis is due to an altered keratinocyte phenotype induced by interleukin-17. <i>British Journal of Dermatology</i> , 2018, 178, 1364-1372.	1.4	24
430	Patient satisfaction with store-and-forward teledermatology. <i>Journal of Telemedicine and Telecare</i> , 2001, 7, 45-46.	1.4	24
431	Cutaneous Leukocyte Trafficking and Psoriasis. <i>Archives of Dermatology</i> , 1994, 130, 494.	1.7	23
432	Ascomycin: an advance in the management of atopic dermatitis. <i>British Journal of Dermatology</i> , 2001, 144, 679-681.	1.4	23

#	ARTICLE	IF	CITATIONS
433	Immunotherapy for psoriasis: from serendipity to selectivity. <i>Lancet, The</i> , 2002, 359, 279-280.	6.3	23
434	Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. <i>British Journal of Dermatology</i> , 2010, 163, 859-862.	1.4	23
435	Chemical consequences of cutaneous photoageing. <i>Chemistry Central Journal</i> , 2012, 6, 34.	2.6	23
436	Exploring the role of prolactin in psoriasis. <i>Archives of Dermatological Research</i> , 2012, 304, 115-118.	1.1	23
437	Cross-linking of structural proteins in ageing skin: an in situ assay for the detection of amine oxidase activity. <i>Biogerontology</i> , 2013, 14, 89-97.	2.0	23
438	Serum insulin-like growth factor 1 and facial ageing: high levels associate with reduced skin wrinkling in a cross-sectional study. <i>British Journal of Dermatology</i> , 2013, 168, 533-538.	1.4	23
439	Lifestyle and youthful looks. <i>British Journal of Dermatology</i> , 2015, 172, 1338-1345.	1.4	23
440	Lipidomics for translational skin research: A primer for the uninitiated. <i>Experimental Dermatology</i> , 2018, 27, 721-728.	1.4	23
441	Enhanced NF- $\kappa$ B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. <i>Nature Communications</i> , 2021, 12, 4741.	5.8	23
442	Cutaneous leukocyte trafficking and psoriasis. <i>Archives of Dermatology</i> , 1994, 130, 494-499.	1.7	23
443	A clinical and histologic mycosis fungoides simulant occurring as a T-cell infiltrate coexisting with B-cell leukemia cutis. <i>Journal of the American Academy of Dermatology</i> , 1995, 33, 341-345.	0.6	22
444	CARD15/NOD2 single nucleotide polymorphisms do not confer susceptibility to type I psoriasis. <i>British Journal of Dermatology</i> , 2004, 151, 675-678.	1.4	22
445	A European perspective on the challenges of managing psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, S81-S84.	0.6	22
446	Langerhans Cell Mobilization Distinguishes between Early-Onset and Late-Onset Psoriasis. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1940-1942.	0.3	22
447	Diurnal and seasonal variation in psoriasis symptoms. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e45-e47.	1.3	22
448	Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-stage, adaptive placebo-controlled trial (APRICOT)*. <i>British Journal of Dermatology</i> , 2022, 186, 245-256.	1.4	22
449	Not all spindled-shaped cells embedded in a collagenous stroma are fibroblasts: recognition of the "collagen-associated dendrophage". <i>Journal of Cutaneous Pathology</i> , 1990, 17, 252-253.	0.7	21
450	Figurate erythema with bullous pemphigoid: a true paraneoplastic phenomenon?. <i>Clinical and Experimental Dermatology</i> , 1999, 24, 446-448.	0.6	21

#	ARTICLE	IF	CITATIONS
451	The CX3CL1-CX3CR1 system and psoriasis. <i>Experimental Dermatology</i> , 2006, 15, 900-903.	1.4	21
452	Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 323-332.	1.3	21
453	Secukinumab for patients failing previous tumour necrosis factor- $\alpha$ inhibitor therapy: results of a randomized open-label study (SIGNATURE). <i>British Journal of Dermatology</i> , 2020, 183, 60-70.	1.4	21
454	Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. <i>British Journal of Dermatology</i> , 2021, 185, 1124-1134.	1.4	21
455	Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 882-893.	1.5	21
456	Abnormal Cutaneous Topobiology: The Molecular Basis for Dermatopathologic Mononuclear Cell Patterns in Inflammatory Skin Disease. <i>Journal of Investigative Dermatology</i> , 1990, 95, S128-S131.	0.3	20
457	CD1 gene expression in human skin. <i>Journal of Dermatological Science</i> , 1993, 6, 206-213.	1.0	20
458	Downregulation and altered spatial pattern of caveolin-1 in chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2002, 147, 701-709.	1.4	20
459	The effect of ageing on phenotype and function of monocyte-derived Langerhans cells. <i>British Journal of Dermatology</i> , 2011, 165, 184-188.	1.4	20
460	<i>In vitro</i> and <i>in vivo</i> studies with tetrahydrocannabinolic acid (THCA) reveal its potential to correct signs of skin ageing. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 415-423.	1.3	20
461	Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells. <i>Molecular BioSystems</i> , 2015, 11, 2198-2209.	2.9	20
462	Over-the-counter anti-ageing topical agents and their ability to protect and repair photoaged skin. <i>Maturitas</i> , 2015, 80, 265-272.	1.0	20
463	Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept. <i>British Journal of Dermatology</i> , 2015, 172, 230-238.	1.4	20
464	Retinoic acid antagonizes basal as well as coal tar and glucocorticoid-induced cytochrome P4501A1 expression in human skin. <i>Carcinogenesis</i> , 1995, 16, 519-524.	1.3	19
465	The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 265-268.	0.6	19
466	Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 $\mu$ g/g ointment; no correlation with extent of psoriasis. <i>Journal of Dermatological Treatment</i> , 2003, 14, 14-21.	1.1	19
467	Retinoic acid receptor $\gamma$ expression and cutaneous ageing. <i>Mechanisms of Ageing and Development</i> , 2004, 125, 465-473.	2.2	19
468	Associations between UVR exposure and basal cell carcinoma site and histology. <i>Cancer Letters</i> , 2004, 216, 191-197.	3.2	19

#	ARTICLE	IF	CITATIONS
469	Treatment of photoaged skin with a cream containing 0.05% isotretinoin and sunscreens. <i>Journal of Dermatological Treatment</i> , 2005, 16, 79-86.	1.1	19
470	Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 415-416.	0.6	19
471	Pilot study of intense pulsed light for the treatment of systemic sclerosis-related telangiectases. <i>British Journal of Dermatology</i> , 2012, 167, 563-569.	1.4	19
472	Dopamine is a novel, direct inducer of catagen in human scalp hair follicles <i>in vitro</i> . <i>British Journal of Dermatology</i> , 2013, 168, 520-525.	1.4	19
473	Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized <scp>VOYAGE</scp> 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1515-1522.	1.3	19
474	Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. <i>British Journal of Dermatology</i> , 2018, 179, 863-871.	1.4	19
475	Proteomic fingerprints of damage in extracellular matrix assemblies. <i>Matrix Biology Plus</i> , 2020, 5, 100027.	1.9	19
476	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. <i>Dermatology and Therapy</i> , 2021, 11, 1357-1372.	1.4	19
477	Phosphoinositide-Mediated Signal Transduction in Normal and Psoriatic Epidermis. <i>Journal of Investigative Dermatology</i> , 1990, 95, S15-S17.	0.3	18
478	Dual wavelength (532 and 633 nm) laser Doppler imaging of plaque psoriasis. <i>British Journal of Dermatology</i> , 2005, 152, 1182-1186.	1.4	18
479	Alefacept in the Treatment of Psoriasis in Patients for Whom Conventional Therapies Are Inadequate. <i>Dermatology</i> , 2005, 211, 256-263.	0.9	18
480	Optimal Management of Severe Plaque Form of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2005, 6, 283-294.	3.3	18
481	The Future of Biological Therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 63-66.	1.6	18
482	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	6.3	18
483	Non-invasive Imaging of Localised Scleroderma for Assessment of Skin Blood Flow and Structure. <i>Acta Dermato-Venereologica</i> , 2016, 96, 641-644.	0.6	18
484	Novel systemic therapies for the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 79-92.	0.9	18
485	Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. <i>British Journal of Dermatology</i> , 2017, 177, 828-836.	1.4	18
486	Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. <i>European Journal of Dermatology</i> , 2018, 28, 356-363.	0.3	18

#	ARTICLE	IF	CITATIONS
487	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. <i>JAMA Dermatology</i> , 2020, 156, 1216.	2.0	18
488	Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. <i>British Journal of Dermatology</i> , 2020, 183, 404-406.	1.4	18
489	Predicting Proteolysis in Complex Proteomes Using Deep Learning. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3071.	1.8	18
490	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e636-e640.	1.3	18
491	Noninvasive Measurement of Skin Autofluorescence Is Increased in Patients with Systemic Sclerosis: An Indicator of Increased Advanced Glycation Endproducts?. <i>Journal of Rheumatology</i> , 2012, 39, 1654-1658.	1.0	17
492	Treatment-Related Restoration of Langerhans Cell Migration in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 268-271.	0.3	17
493	Psoriasis. <i>Dermatologic Clinics</i> , 2015, 33, 161-166.	1.0	17
494	Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. <i>British Journal of Dermatology</i> , 2015, 172, 933-939.	1.4	17
495	Distinctive clinical and histological characteristics of atrophic and hypertrophic facial photoageing. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 762-768.	1.3	17
496	Gliadins bind to reticulin in a lectin-like manner. <i>Archives of Dermatological Research</i> , 1987, 279, 232-235.	1.1	16
497	Cost-Effectiveness Analysis of Topical Calcipotriol versus Short- Contact Dithranol. <i>Pharmacoeconomics</i> , 2000, 18, 469-476.	1.7	16
498	Activation of oral keratinocytes by mercuric chloride: relevance to dental amalgam-induced oral lichenoid reactions. <i>British Journal of Dermatology</i> , 2001, 144, 1024-1032.	1.4	16
499	A review of tazarotene in the treatment of photodamaged skin. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 71-76.	1.3	16
500	An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. <i>British Journal of Dermatology</i> , 2013, 168, 374-380.	1.4	16
501	A photonumeric scale for the assessment of atrophic facial photodamage. <i>British Journal of Dermatology</i> , 2018, 178, 1190-1195.	1.4	16
502	Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis. <i>Value in Health</i> , 2018, 21, 1010-1018.	0.1	16
503	What are the barriers to physical activity in patients with chronic plaque psoriasis?*. <i>British Journal of Dermatology</i> , 2020, 183, 1094-1102.	1.4	16
504	Interventions for guttate psoriasis. <i>The Cochrane Library</i> , 2000, , CD001213.	1.5	15



#	ARTICLE	IF	CITATIONS
505	Inpatient management of psoriasis: a multicentre service review to establish national admission standards. <i>British Journal of Dermatology</i> , 2007, 158, 266-272.	1.4	15
506	Beyond skin: the need for a new approach to the management of psoriasis in primary care. <i>British Journal of General Practice</i> , 2012, 62, 568-569.	0.7	15
507	The acceptability and usefulness of mindfulness-based cognitive therapy for people living with psoriasis: a qualitative study. <i>British Journal of Dermatology</i> , 2015, 172, 823-825.	1.4	15
508	The role of personal models in clinical management: Exploring health care providers' beliefs about psoriasis. <i>British Journal of Health Psychology</i> , 2016, 21, 114-134.	1.9	15
509	A novel mutation in <i>IL36RN</i> underpins childhood pustular dermatosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 302-305.	1.3	15
510	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. <i>Trials</i> , 2018, 19, 465.	0.7	15
511	Langerhans cells express human $\beta$ -defensin 3: relevance for immunity during skin ageing. <i>British Journal of Dermatology</i> , 2018, 179, 1170-1171.	1.4	15
512	The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership. <i>British Journal of Dermatology</i> , 2019, 181, 871-873.	1.4	15
513	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 1265-1271.	1.4	15
514	Investigation of Cytomegalovirus and Human Herpes Viruses 6 and 7 as Possible Causative Antigens in Psoriasis. <i>Acta Dermato-Venereologica</i> , 2000, 80, 404-406.	0.6	14
515	Genetic susceptibility to psoriasis: an emerging picture. <i>Genome Medicine</i> , 2009, 1, 72.	3.6	14
516	Providing lifestyle behaviour change support for patients with psoriasis: an assessment of the existing training competencies across medical and nursing health professionals. <i>British Journal of Dermatology</i> , 2014, 171, 602-608.	1.4	14
517	Epicutaneous exposure to proteins and skin immune function. <i>European Journal of Dermatology</i> , 2014, 24, 10-14.	0.3	14
518	Brain inflammation and psoriasis: a [ <sup>11</sup> C]-(R)-PK11195 positron emission tomography study. <i>British Journal of Dermatology</i> , 2016, 175, 1082-1084.	1.4	14
519	Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. <i>British Journal of Dermatology</i> , 2019, 181, 256-264.	1.4	14
520	Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis. <i>JAMA Dermatology</i> , 2021, 157, 66.	2.0	14
521	Contact dermatitis from topical auranofin. <i>Journal of the American Academy of Dermatology</i> , 1995, 32, 813-814.	0.6	13
522	Pyoderma Gangrenosum Masquerading as Dermatitis Artefacta. <i>Archives of Dermatology</i> , 2006, 142, 1508.	1.7	13

#	ARTICLE	IF	CITATIONS
523	The challenges of assessing patients' medication beliefs: a qualitative study. BMC Health Services Research, 2017, 17, 119.	0.9	13
524	The association between psoriasis and coeliac disease. British Journal of Dermatology, 2017, 177, e329-e330.	1.4	13
525	The systemic influence of chronic smoking on skin structure and mechanical function. Journal of Pathology, 2020, 251, 420-428.	2.1	13
526	Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single-centre cross-sectional study. British Journal of Dermatology, 2021, 185, 441-443.	1.4	13
527	The promise and challenges of cell therapy for psoriasis*. British Journal of Dermatology, 2021, 185, 887-898.	1.4	13
528	Topical auranofin ointment for the treatment of plaque psoriasis. Journal of the American Academy of Dermatology, 1995, 33, 517-519.	0.6	12
529	Chronic granulomatous disease and acute neutrophilic dermatosis. Clinical and Experimental Dermatology, 1999, 24, 368-371.	0.6	12
530	Keloidal scleroderma. Clinical and Experimental Dermatology, 2003, 28, 171-173.	0.6	12
531	Topical Treatments for Scalp Psoriasis. Drugs, 2008, 68, 2293-2302.	4.9	12
532	Utilizing the hair follicle to dissect the regulation and autocrine/paracrine activities of prolactin in humans. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E1311-E1312.	1.8	12
533	Psoriasis treatment and management - a systematic review of full economic evaluations. British Journal of Dermatology, 2015, 172, 574-583.	1.4	12
534	A visual literacy course for dermatology trainees. British Journal of Dermatology, 2017, 177, 310-311.	1.4	12
535	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 2019, 180, 894-901.	1.4	12
536	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	2.0	12
537	Cyclophilin Content of Normal and Psoriatic Epidermis. Journal of Investigative Dermatology, 1990, 94, 436-440.	0.3	11
538	Papuloerythroderma of Ofuji associated with acute myeloid leukaemia. Clinical and Experimental Dermatology, 2003, 28, 277-279.	0.6	11
539	Psoriasis: future research needs and goals for the twenty-first century. Dermatologic Clinics, 2004, 22, 493-499.	1.0	11
540	The Greater Patient concept. British Journal of Dermatology, 2007, 158, 071027220355005-???	1.4	11

#	ARTICLE	IF	CITATIONS
541	An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the <i>REL</i> gene. <i>British Journal of Dermatology</i> , 2013, 168, 864-866.	1.4	11
542	Cutaneous <i>Mycobacterium haemophilum</i> infection in a patient receiving infliximab for psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 446-447.	1.4	11
543	Guttate psoriasis is associated with an intermediate phenotype of impaired Langerhans cell migration. <i>British Journal of Dermatology</i> , 2014, 171, 409-411.	1.4	11
544	Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the <i>CRYSTEL</i> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 468-473.	1.3	11
545	Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. <i>Journal of Dermatological Treatment</i> , 2015, 26, 329-334.	1.1	11
546	Defining tissue proteomes by systematic literature review. <i>Scientific Reports</i> , 2018, 8, 546.	1.6	11
547	An art-based visual literacy training course to enhance clinical skills in dermatology trainees. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e310-e312.	1.3	11
548	Differences in Clinical Features and Comorbid Burden between HLA-C*06:02 Carrier Groups in >9,000 People with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1617-1628.e10.	0.3	11
549	Resetting the Research Agenda for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2003, 120, ix-x.	0.3	10
550	What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010. <i>Clinical and Experimental Dermatology</i> , 2011, 36, 585-589.	0.6	10
551	Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis. <i>British Journal of Dermatology</i> , 2015, 173, 1271-1273.	1.4	10
552	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. <i>British Journal of Dermatology</i> , 2017, 177, 587-590.	1.4	10
553	Lysyl oxidase activity in human skin is increased by chronic ultraviolet radiation exposure and smoking. <i>British Journal of Dermatology</i> , 2017, 176, 1376-1378.	1.4	10
554	Mass spectrometry-based proteomics reveals the distinct nature of the skin proteomes of photoaged compared to intrinsically aged skin. <i>International Journal of Cosmetic Science</i> , 2019, 41, 118-131.	1.2	10
555	Understanding the experience of sleep disturbance in psoriasis: a qualitative exploration using the Common-Sense Model of Self-Regulation. <i>British Journal of Dermatology</i> , 2019, 180, 1397-1404.	1.4	10
556	Multiple glomus tumours, Coats' disease and basic fibroblast growth factor. <i>British Journal of Dermatology</i> , 1997, 137, 454-456.	1.4	9
557	An investigation of the effect of prolonged glove wearing on the hand skin health of dental healthcare workers. <i>Journal of Dentistry</i> , 2002, 30, 233-241.	1.7	9
558	Competency assessment of dermatology trainees in the UK. <i>Clinical and Experimental Dermatology</i> , 2004, 29, 571-575.	0.6	9

#	ARTICLE	IF	CITATIONS
559	Worry and Pathological Worry in Patients with Psoriasis: Cross Sectional and Longitudinal Analyses of the Penn State Worry Questionnaire (PSWQ) in Four Samples of Patients. <i>Journal of Clinical Psychology in Medical Settings</i> , 2005, 12, 143-152.	0.8	9
560	Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 206-209.	1.4	9
561	Communicating Cardiovascular Disease Risk to People with Psoriasis: What Techniques do Practitioners Use?. <i>International Journal of Behavioral Medicine</i> , 2016, 23, 168-178.	0.8	9
562	A new in vitro assay to test UVR protection of dermal extracellular matrix components by a flat spectrum sunscreen. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2017, 175, 58-64.	1.7	9
563	Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal. <i>British Journal of Dermatology</i> , 2019, 180, 1348-1351.	1.4	9
564	Progress to Date in Advancing Stratified Medicine in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 619-626.	3.3	9
565	Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. <i>Clinical and Translational Science</i> , 2020, 13, 400-409.	1.5	9
566	Peptide location fingerprinting reveals modification-associated biomarker candidates of ageing in human tissue proteomes. <i>Aging Cell</i> , 2021, 20, e13355.	3.0	9
567	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. <i>Clinics in Dermatology</i> , 2021, 39, 467-478.	0.8	9
568	Topical retinoic acid changes the epidermal cell surface glycosylation pattern towards that of a mucosal epithelium. <i>British Journal of Dermatology</i> , 1996, 134, 431-436.	1.4	9
569	How best to halt and/or revert UV-induced skin ageing: strategies, facts and fiction. <i>Experimental Dermatology</i> , 2008, 17, 228-240.	1.4	9
570	A pilot study of body image dissatisfaction and the psychological impact of systemic sclerosis-related telangiectases. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 12-7.	0.4	9
571	Pilot study assessing pathophysiology and healing of digital ulcers in patients with systemic sclerosis using laser Doppler imaging and thermography. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 100-105.	0.4	9
572	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 727-740.	1.4	9
573	Mechanisms of action of retinoic acid in skin repair. <i>British Journal of Dermatology</i> , 1992, 127, 21-24.	1.4	8
574	T-Cell-Targeted Biologics for Psoriasis. <i>Inflammation and Allergy: Drug Targets</i> , 2004, 3, 157-161.	3.1	8
575	Feasibility study to inform the design of a UK multi-centre randomised controlled trial of prophylactic antibiotics for the prevention of recurrent cellulitis of the leg. <i>Trials</i> , 2007, 8, 3.	0.7	8
576	Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 2-8.	1.3	8

#	ARTICLE	IF	CITATIONS
577	Markers of health and disease and pigmented spots in a middle-aged population. <i>British Journal of Dermatology</i> , 2015, 173, 1550-1552.	1.4	8
578	Do English healthcare settings use "Choice Architecture"™ principles in promoting healthy lifestyles for people with psoriasis? An observational study. <i>BMC Health Services Research</i> , 2015, 15, 215.	0.9	8
579	Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. <i>British Journal of Dermatology</i> , 2018, 178, 1297-1307.	1.4	8
580	Basal cell carcinoma genetic susceptibility increases the rate of skin ageing: a Mendelian randomization study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 97-100.	1.3	8
581	Heterogeneity of fibrillin-rich microfibrils extracted from human skin of diverse ethnicity. <i>Journal of Anatomy</i> , 2020, 237, 478-486.	0.9	8
582	The relationship between PASI and DLQI with itch, stress, and depression: Do we need additional decision-making tools in psoriasis?. <i>Dermatologic Therapy</i> , 2020, 33, e13276.	0.8	8
583	Implementation of the PsoWell <sub>2</sub> Model for the Management of People with Complex Psoriasis. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00445.	0.6	8
584	Paradoxical eczema in patients with psoriasis receiving biologics: a case series. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1174-1178.	0.6	8
585	Psoriasis. I. Pathogenesis. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 98-101.	0.6	7
586	The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor-receptor 1 in psoriasis.. <i>British Journal of Dermatology</i> , 2001, 145, 1027-1028.	1.4	7
587	What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 664-667.	0.6	7
588	Management of psoriasis in pregnancy: time to deliver?. <i>British Journal of Dermatology</i> , 2010, 163, 235-235.	1.4	7
589	No impairment of monocyte-derived Langerhans cell phenotype or function in early-onset psoriasis. <i>Clinical and Experimental Dermatology</i> , 2012, 37, 40-47.	0.6	7
590	Drug therapies in dermatology. <i>Clinical Medicine</i> , 2014, 14, 47-53.	0.8	7
591	The relationship between sleep disturbance, symptoms and daytime functioning in psoriasis: a prospective study integrating actigraphy and experience sampling methodology. <i>Sleep Medicine</i> , 2020, 72, 144-149.	0.8	7
592	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. <i>Trials</i> , 2020, 21, 158.	0.7	7
593	Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2022, 12, 1431-1446.	1.4	7
594	PSORIASIS AND INTERFERON. <i>Lancet</i> , The, 1986, 328, 342-343.	6.3	6

#	ARTICLE	IF	CITATIONS
595	Tretinoin for Hyperpigmentation in Black Patients. <i>New England Journal of Medicine</i> , 1993, 329, 1503-1503.	13.9	6
596	Assessment of topical retinoids for the treatment of Far-East Asian skin. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, S104-S107.	0.6	6
597	Dowling Oration delivered at the Royal College of Physicians, London, Friday 5 June 1998. Retinoids: renaissance and reformation. <i>Clinical and Experimental Dermatology</i> , 1999, 24, 329-335.	0.6	6
598	No Association between Polymorphisms in the Interleukin-15 Gene and Early-Onset Psoriasis in a UK Cohort Suggests Heterogeneity for this Susceptibility Locus Identified in Chinese Psoriasis Patients. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2904-2905.	0.3	6
599	Alice, Eloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts. <i>British Journal of Dermatology</i> , 2009, 161, 1-30.	1.4	6
600	What's new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 688-692.	0.6	6
601	A randomised, controlled trial of a 4% cutaneous emulsion of sodium cromoglicate in treatment of atopic dermatitis in children. <i>Journal of Dermatological Treatment</i> , 2015, 26, 291-296.	1.1	6
602	Disentangling the effects of circulating IGF-1, glucose, and cortisol on features of perceived age. <i>Age</i> , 2015, 37, 9771.	3.0	6
603	Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise. <i>British Journal of Dermatology</i> , 2016, 174, 212-215.	1.4	6
604	Genetic interaction between placental growth factor and vascular endothelial growth factor A in psoriasis. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 302-308.	0.6	6
605	Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting. <i>Dermatologic Therapy</i> , 2020, 33, e13166.	0.8	6
606	Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1482-1490.	1.1	6
607	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2129-2137.	0.3	6
608	The incidence of psoriasis in Chile: an analysis of the National Waiting List Repository. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1262-1269.	0.6	6
609	Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2409-2414.	1.3	6
610	Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. <i>Dermatology and Therapy</i> , 2022, 12, 81-95.	1.4	6
611	(8) Comparison of psoriasis treated with cyclosporin alone or cyclosporin and clobetasol propionate. <i>British Journal of Dermatology</i> , 1987, 117, 35-36.	1.4	5
612	Curly Lusterless Hair: Anatomic Surface Changes on Transplanted Hair Shafts. <i>The Journal of Dermatologic Surgery and Oncology</i> , 1993, 19, 1129-1130.	0.8	5

#	ARTICLE	IF	CITATIONS
613	An Examination of the Psychometric Properties and Factor Structure of the Feelings of Stigmatization Questionnaire. <i>Journal of Clinical Psychology in Medical Settings</i> , 2007, 14, 248-257.	0.8	5
614	Paradoxical exacerbation of chronic plaque psoriasis by sorafenib. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 407-409.	0.6	5
615	What's new in psoriasis treatment? An analysis of systematic reviews published in 2015. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 759-765.	0.6	5
616	Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study*. <i>British Journal of Dermatology</i> , 2021, 185, 952-960.	1.4	5
617	Multifaceted amelioration of cutaneous photoageing by (0.3%) retinol. <i>International Journal of Cosmetic Science</i> , 2022, 44, 625-635.	1.2	5
618	Wirksamkeit und Sicherheit von Tacalcitol-Salbe in der Langzeitanwendung bei chronischer Plaque Psoriasis. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. <i>Zeitschrift für Hautkrankheiten</i> , 2002, 77, 424-432.	0.0	4
619	Therapeutic potential of macrolide immunosuppressants in dermatology. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 125-137.	1.9	4
620	Making a point about the safe disposal of sharps in patients on biological therapies. <i>British Journal of Dermatology</i> , 2008, 159, 491-492.	1.4	4
621	A Tooth for an Eye: Cicatricial Pemphigoid and the Osteo-Odonto-Keratoprosthesis. <i>Archives of Dermatology</i> , 2010, 146, 1188-9.	1.7	4
622	Improving clinical trial design in psoriasis: Perspectives from the global dermatology community. <i>Journal of Dermatological Treatment</i> , 2011, 22, 187-193.	1.1	4
623	Biologics for psoriasis: current evidence and future use. <i>British Journal of Dermatology</i> , 2012, 167, 1-2.	1.4	4
624	Interventions for photodamaged skin. <i>The Cochrane Library</i> , 2015, 2015, CD001782.	1.5	4
625	Interleukin-17 and interleukin-23 regulate Langerhans cell migration. <i>British Journal of Dermatology</i> , 2016, 175, 622-624.	1.4	4
626	Developing a protocol to identify and prioritize research questions for psoriasis: a James Lind Alliance Priority Setting Partnership. <i>British Journal of Dermatology</i> , 2018, 178, 1383-1387.	1.4	4
627	Long-term, real-world efficacy of biologics for psoriasis: a single centre's experience. <i>British Journal of Dermatology</i> , 2019, 181, 599-601.	1.4	4
628	The short-term effect of levocetirizine on quality of life, stress, and depression in itchy psoriasis patients. <i>Dermatologic Therapy</i> , 2020, 33, e13179.	0.8	4
629	Remodelling of fibrillin-rich microfibrils by solar-simulated radiation: impact of skin ethnicity. <i>Photochemical and Photobiological Sciences</i> , 2020, 19, 1160-1167.	1.6	4
630	An evaluation of dermatology patients shielding during the COVID-19 outbreak. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 193-194.	0.6	4



#	ARTICLE	IF	CITATIONS
631	Research priorities and identification of a health service delivery model for psoriasis from the UK Psoriasis Priority Setting Partnership. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 276-285.	0.6	4
632	Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e496-e498.	1.3	4
633	Defining trajectories of response in patients with psoriasis treated with biologic therapies. <i>British Journal of Dermatology</i> , 2021, 185, 825-835.	1.4	4
634	Patient preferences for stratified medicine in psoriasis: a discrete choice experiment. <i>British Journal of Dermatology</i> , 2021, 185, 978-987.	1.4	4
635	The art of observation: visual literacy for dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e809-e811.	1.3	4
636	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1872-1878.	0.3	4
637	Influence of menopause and hormone replacement therapy on epidermal ageing and skin biomechanical function. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	4
638	Efficacy of topical cyclosporin a in the treatment of alopecia areata. <i>Journal of Dermatological Treatment</i> , 1994, 5, 77-79.	1.1	3
639	Mobilization of epidermal Langerhans cells - reply from the authors. <i>British Journal of Dermatology</i> , 2000, 143, 894-894.	1.4	3
640	Streptococcal infection may make psoriasis worse but do antibiotics help?. <i>British Journal of Dermatology</i> , 2004, 151, 244-245.	1.4	3
641	Ixekizumab for psoriasis – Authors' reply. <i>Lancet, The</i> , 2016, 387, 226-227.	6.3	3
642	Development of clinical diagnostic criteria for chronic plaque psoriasis: an international eDelphi study. <i>British Journal of Dermatology</i> , 2021, 185, 455-456.	1.4	3
643	Concordance and timing in recording cancer events in primary care, hospital and mortality records for patients with and without psoriasis: A population-based cohort study. <i>PLoS ONE</i> , 2021, 16, e0254661.	1.1	3
644	Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey. <i>Rheumatology and Therapy</i> , 2021, 8, 1741-1758.	1.1	3
645	Reduced cutaneous CD200:CD200R1 signaling in psoriasis enhances neutrophil recruitment to skin. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	3
646	Incidence and prevalence of psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in the Teleprimary Care (TPC <sup>Â</sup> ) clinical information system from 2010 to 2020. <i>British Journal of Dermatology</i> , 2022, 187, 713-721.	1.4	3
647	Psoriasis. <i>BMJ: British Medical Journal</i> , 1986, 293, 266-266.	2.4	2
648	Topical retinoic acid for photoaged skin: Therapeutic effects and mechanisms. <i>Journal of Dermatological Treatment</i> , 1996, 7, S23-S27.	1.1	2

#	ARTICLE	IF	CITATIONS
649	Topical retinoic acid changes the epidermal cell surface glycosylation pattern towards that of a mucosal epithelium. <i>British Journal of Dermatology</i> , 1996, 134, 431-436.	1.4	2
650	Immunotherapy of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 1997, 1, 175-184.	0.6	2
651	Modern management of psoriasis. <i>Clinical Medicine</i> , 2005, 5, 564-568.	0.8	2
652	Biological therapy for psoriasis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2006, 67, 184-187.	0.2	2
653	Liver X receptor $\beta$ : maintenance of epidermal expression in intrinsic and extrinsic skin aging. <i>Age</i> , 2009, 31, 365-372.	3.0	2
654	Evidence for an "anti-ageing" product may not be so clear as it appears: reply from authors. <i>British Journal of Dermatology</i> , 2009, 161, 1208-1209.	1.4	2
655	An investigation into the blood-flow characteristics of telangiectatic skin lesions in systemic sclerosis using dual-wavelength laser Doppler imaging. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 618-620.	0.6	2
656	Alemtuzumab and chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2013, 169, 184-186.	1.4	2
657	Systems medicine and psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 560-562.	1.4	2
658	Reply to "Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials": reply from the authors. <i>British Journal of Dermatology</i> , 2017, 177, 1766-1767.	1.4	2
659	Keratinocytes derived from late-onset-psoriasis skin do not impair Langerhans cell migration. <i>British Journal of Dermatology</i> , 2018, 179, 1208-1209.	1.4	2
660	The Skin Science Foundation: Promoting Skin Health through Research. <i>Journal of Investigative Dermatology</i> , 2020, 140, S189-S190.	0.3	2
661	The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. <i>British Journal of Dermatology</i> , 2020, 183, 981-983.	1.4	2
662	Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 928-937.	1.3	2
663	Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e498-e501.	1.3	2
664	AB0532...MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1297-1298.	0.5	2
665	Physical activity is important for cardiovascular health and cardiorespiratory fitness in patients with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 289-296.	0.6	2
666	How do dermatologists' personal models inform a patient-centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast). <i>British Journal of Dermatology</i> , 2022, , .	1.4	2

#	ARTICLE	IF	CITATIONS
667	A rapid access clinic for psoriasis: first experiences. <i>British Journal of Dermatology</i> , 2022, 187, 426-428.	1.4	2
668	(11) Oesophageal strictures in cicatricial pemphigoid. <i>British Journal of Dermatology</i> , 1987, 117, 37-37.	1.4	1
669	Treatment Options for Photodamaged Skin. <i>Skin Pharmacology and Physiology</i> , 1997, 10, 1-11.	1.1	1
670	GMDP and psoriasis. <i>Lancet, The</i> , 1998, 352, 1857.	6.3	1
671	A painful spot on the nose. <i>Lancet, The</i> , 1998, 351, 566.	6.3	1
672	A 62-year-old man presenting with widespread nodulo-ulcerative cutaneous lesions. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 115-119.	0.6	1
673	Fibulin-2 and its association with fibrillin-rich microfibrils in the papillary dermis of photoaged skin. <i>British Journal of Dermatology</i> , 2002, 146, 712-712.	1.4	1
674	Ciclosporin in psoriasis consensus statement: reply from authors. <i>British Journal of Dermatology</i> , 2005, 152, 811-811.	1.4	1
675	Efalizumab. <i>American Journal of Clinical Dermatology</i> , 2005, 6, 119-120.	3.3	1
676	Future Therapeutic Directions for the Treatment of Psoriasis. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2009, 100, 28-31.	0.2	1
677	Commentary: Biologics for psoriasis: steps to heaven 17. <i>British Journal of Dermatology</i> , 2012, 167, 715-716.	1.4	1
678	So you want to be a clinical academic. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012, 73, C23-C25.	0.2	1
679	Dr. Murray, et al reply. <i>Journal of Rheumatology</i> , 2013, 40, 206.2-206.	1.0	1
680	A quasiquicentennial reflection on psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 231-233.	1.4	1
681	Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2014, 25, 61-62.	1.1	1
682	The International Psoriasis Council: Advancing Knowledge, Enhancing Care. <i>Dermatologic Clinics</i> , 2015, 33, ix-xii.	1.0	1
683	Treatment patterns and outcomes among adults admitted to hospital in the U.K. due to plaque or erythrodermic psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, e52-e54.	1.4	1
684	Medication non-adherence: the hidden problem in clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 923-924.	1.3	1

#	ARTICLE	IF	CITATIONS
685	How does the International League of Dermatological Societies promote skin health for the world?. British Journal of Dermatology, 2019, 180, 1281-1283.	1.4	1
686	â€œMind the gapâ€™: what patients and clinicians believe is â€œunknownâ€™ about psoriasis. British Journal of Dermatology, 2020, 183, 399-400.	1.4	1
687	Immediate global support is needed for Myanmar. British Journal of Dermatology, 2021, 185, 466-467.	1.4	1
688	AB0528â€¦COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR. Annals of the Rheumatic Diseases, 2021, 80, 1293-1294.	0.5	1
689	Adalimumab for the treatment of psoriasis. Expert Review of Dermatology, 2009, 4, 15-21.	0.3	1
690	Can Skin Aging Contribute to Systemic Inflammaging?. Journal of Investigative Dermatology, 2022, 142, 484-485.	0.3	1
691	Epidermal and dermal abnormalities. European Journal of Dermatology, 2002, 12, XIX-XX.	0.3	1
692	In search of the source of hyperprolactinaemia in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2011, 29, 1060.	0.4	1
693	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. Efficacy and Mechanism Evaluation, 2022, 9, 1-106.	0.9	1
694	(25) Long-term follow-up of low-dose cyclosporin treatment for psoriasis. British Journal of Dermatology, 1988, 119, 56-57.	1.4	0
695	Cyclosporin A does not Inhibit Epidermal Growth at Therapeutic Levels. Journal of Investigative Dermatology, 1988, 90, 536.	0.3	0
696	A Photonumeric Scale for the Assessment of Cutaneous Photodamage-Reply. Archives of Dermatology, 1992, 128, 1407.	1.7	0
697	Effect of Tretinoin on Collagen Formation in Photodamaged Skin. New England Journal of Medicine, 1993, 329, 2038-2039.	13.9	0
698	â€œBrooke of Manchesterâ€™. British Journal of Dermatology, 2000, 143, 26-29.	1.4	0
699	Psoriasis 2000: the state-of-the-art today ... and tomorrow. British Journal of Dermatology, 2001, 144, 1-1.	1.4	0
700	Enumeration of the frequency of Langerhans cells in epidermis. British Journal of Dermatology, 2002, 147, 1277-1278.	1.4	0
701	Enumeration of the frequency of Langerhans cells in epidermis: reply from authors. British Journal of Dermatology, 2002, 147, 1278-1278.	1.4	0
702	Die Zytokin-Blocker in der Dermatologie. Cytokine blocking agents in dermatology. Zeitschrift FÃ¼r Hautkrankheiten, 2002, 77, 663-668.	0.0	0

#	ARTICLE	IF	CITATIONS
703	Ciclosporin in psoriasis consensus statement. British Journal of Dermatology, 2005, 152, 811-811.	1.4	0
704	Controversies in Experimental Dermatology. Viewpoint 5. Experimental Dermatology, 2005, 14, 398-399.	1.4	0
705	Anti-TNF drugs in psoriasis and IBD - Where are we going?. Future Prescriber, 2006, 7, 14-20.	0.1	0
706	Guidelines for Logbook for registration of training activities in dermatology and venereology: report from the Board of Dermatology and Venereology. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 850-851.	1.3	0
707	Viewpoint 2. Experimental Dermatology, 2008, 17, 230-231.	1.4	0
708	Effects vs Improvement of Photoaged Skinâ€”Reply. Archives of Dermatology, 2010, 146, .	1.7	0
709	Twenty top tips to triumph in dermatology. British Journal of Dermatology, 2012, 167, 445-446.	1.4	0
710	Biologic therapies in dermatology. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, 12-17.	0.2	0
711	Scanning acoustic microscopy of biological cryosections: the effect of local thickness on apparent acoustic wave speed. Materials Research Society Symposia Proceedings, 2014, 1621, 143-148.	0.1	0
712	A fresh look at T cells in psoriasis. British Journal of Dermatology, 2015, 173, 891-892.	1.4	0
713	THU0187â€¦Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials. Annals of the Rheumatic Diseases, 2016, 75, 253.1-253.	0.5	0
714	Celebrating the 50th Anniversary of ESDR. Journal of Investigative Dermatology, 2020, 140, S145-S146.	0.3	0
715	The Future of ESDR. Journal of Investigative Dermatology, 2020, 140, S192-S193.	0.3	0
716	Professor Lionel Fry (1933â€”2021). British Journal of Dermatology, 2021, 185, 237-238.	1.4	0
717	Tender facial nodules in a man receiving adalimumab for psoriasis. Clinical and Experimental Dermatology, 2021, , .	0.6	0
718	Restoration of collagen and elastic fibre networks following treatment of photoaged skin with SerAˆnnesse, a novel overâ€”theâ€”counter antiâ€”ageing product. Journal of the European Academy of Dermatology and Venereology, 2022, 36, e43.	1.3	0
719	Photoageing. , 2000, , 437-440.		0
720	Life threatening complications of dermatological therapy. Clinical and Experimental Dermatology, 2001, 26, 217-218.	0.6	0

#	ARTICLE	IF	CITATIONS
721	Topical retinoids for the ageing face. , 2002, , 13-23.		0
722	Photoageing. , 2003, , 399-401.		0
723	Anti-aging Effects of Retinoids and Mechanisms of Action. Basic and Clinical Dermatology, 2007, , 77-102.	0.1	0
724	A photonumeric scale for the assessment of cutaneous photodamage. Archives of Dermatology, 1992, 128, 1406-1407.	1.7	0
725	Does the lifestyle of patients with psoriasis affect their illness?. Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 643-654.	0.1	0
726	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. Programme Grants for Applied Research, 2022, 10, 1-240.	0.4	0
727	Photoaging. , 0, , 326-336.		0
728	Secukinumab improves the quality of life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open-label study (SIGNATURE). , 2022, 1, 207-218.		0